Neurology®
The most widely read and highly cited peer-reviewed Neurology journal
Quick Search
Advanced Search
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fusco, C.
Right arrow Articles by Lombardi, M. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fusco, C.
Right arrow Articles by Lombardi, M. L.
Related Collections
Right arrow Multiple sclerosis
Neurology 2001;57:1976-1979
© 2001 American Academy of Neurology
Articles

HLA-DRB1*1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis

C. Fusco, MD;, V. Andreone, MD;, G. Coppola, MD;, V. Luongo, PhD;, F. Guerini, PhD;, E. Pace, MD;, C. Florio, MD;, G. Pirozzi, PhD;, R. Lanzillo, MD;, P. Ferrante, MD;, P. Vivo, MD;, M. Mini, MD;, M. Macrì, MD;, G. Orefice, MD and M. L. Lombardi, PhD

From the Servizio Immunoematologia e Trasfusione (Drs. Fusco, Pace, and Macri), Divisione di Neurologia A.O.R.N. (Drs. Andreone, Florio, and Vivo), A. Cardarelli, Napoli; Dipartimento di Scienze Neurologiche (Drs. Coppola, Lanzillo, and Orefice), Università Federico II, Napoli; Laboratorio di Biologia e Unità Sclerosi Multipla (Drs. Guerini and Mini), Fondazione Don C. Gnocchi ONLUS, IRCCS, Milan; Dipartimento di Scienze Precliniche, Università di Milano (Dr. Ferrante); and Oncologia Sperimentale C-Immunologia (Drs. Luongo, Pirozzi, and Lombardi), Istituto Nazionale Tumori, Napoli, Italy.

Address correspondence and reprint requests to Dr. Maria Luisa Lombardi, Via Raffaele Calvanico 13, 80131 Napoli, Italy; e-mail: mllombardi{at}yahoo.com

Background:— Copolymer 1 (Cop-1) is a random synthetic amino acid copolymer, effective in the treatment of the relapsing-remitting form of MS (RRMS). In vitro and in vivo studies suggest that the mechanism of Cop-1 involves its binding to major histocompatibility complex class II molecules as an initial step.

Objective:— To assess a possible relationship between human leukocyte antigen (HLA) alleles and response to Cop-1 therapy.

Methods:— Eighty-three patients with RRMS, 44 treated with Cop-1 and 39 with interferon ß-1a (IFNß-1a) for 2 years, were typed by molecular methods for HLA class II genes and subgrouped according to clinical outcome.

Results:— Data have shown a possible positive correlation between presence of DRB1*1501 and response to Cop-1 therapy (p = 0.008). No relationship between HLA alleles and therapy has been found in IFNß-1a treated patients.

Conclusions:— Results suggest that DRB1*1501 might be relevant for the clinical outcome in Cop-1 treated patients and, if confirmed in larger studies, it could be helpful in the selection of RRMS patients for different therapeutic options.




This article has been cited by other articles:


Home page
 NeurologyHome page
D. J. Pappas and J. R. Oksenberg
Multiple sclerosis pharmacogenomics: Maximizing efficacy of therapy
Neurology, January 5, 2010; 74(1_Supplement_1): S62 - S69.
[Abstract] [Full Text] [PDF]

Home page
 Therapeutic Advances in Neurological DisordersHome page
P. L. De Jager
Review: Identifying patient subtypes in multiple sclerosis and tailoring immunotherapy: challenges for the future
Therapeutic Advances in Neurological Disorders, November 1, 2009; 2(6): 369 - 377.
[Abstract] [PDF]

Home page
 BrainHome page
D. T. Okuda, R. Srinivasan, J. R. Oksenberg, D. S. Goodin, S. E. Baranzini, A. Beheshtian, E. Waubant, S. S. Zamvil, D. Leppert, P. Qualley, et al.
Genotype-Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures
Brain, January 1, 2009; 132(1): 250 - 259.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
E. Waubant, S. Vukusic, L. Gignoux, F. D. Dubief, I. Achiti, S. Blanc, C. Renoux, and C. Confavreux
Clinical characteristics of responders to interferon therapy for relapsing MS
Neurology, July 22, 2003; 61(2): 184 - 189.
[Abstract] [Full Text] [PDF]